{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:32:22Z","timestamp":1786116742116,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100014031","name":"Cancer Research Fund in Norrland","doi-asserted-by":"publisher","award":["AMP 23-1127"],"award-info":[{"award-number":["AMP 23-1127"]}],"id":[{"id":"10.13039\/501100014031","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002960","name":"Region V\u00e4sterbotten","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002960","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001725","name":"Royal Swedish Academy of Sciences","doi-asserted-by":"publisher","award":["LM2023-0012"],"award-info":[{"award-number":["LM2023-0012"]}],"id":[{"id":"10.13039\/501100001725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001725","name":"Royal Swedish Academy of Sciences","doi-asserted-by":"publisher","award":["LM2021-0010"],"award-info":[{"award-number":["LM2021-0010"]}],"id":[{"id":"10.13039\/501100001725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007067","name":"The Kempe Foundations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007067","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006246","name":"Anna Ceder's Foundation for Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017636","name":"Cancer Centre Amsterdam","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017636","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["NCT05524090"],"award-info":[{"award-number":["NCT05524090"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010794","name":"Umea University Faculty of Medicine","doi-asserted-by":"publisher","award":["FS 2.1.6-121-2"],"award-info":[{"award-number":["FS 2.1.6-121-2"]}],"id":[{"id":"10.13039\/501100010794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003748","name":"Swedish Society for Medical Research","doi-asserted-by":"publisher","award":["TG-23-0464"],"award-info":[{"award-number":["TG-23-0464"]}],"id":[{"id":"10.13039\/501100003748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004885","name":"Ume\u00e5 Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004885","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Swedish Society of Medicine","doi-asserted-by":"publisher","award":["SLS-960379"],"award-info":[{"award-number":["SLS-960379"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Swedish Society of Medicine","doi-asserted-by":"publisher","award":["SLS-984271"],"award-info":[{"award-number":["SLS-984271"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009336","name":"Bengt Ihre Research Fund","doi-asserted-by":"publisher","award":["SLS-960529"],"award-info":[{"award-number":["SLS-960529"]}],"id":[{"id":"10.13039\/501100009336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","hpbonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["HPB"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.hpb.2026.04.451","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T23:36:59Z","timestamp":1776901019000},"page":"932-944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant multiagent chemotherapy or upfront surgery for primary resectable pancreatic cancer \u2013 A retrospective intention-to-treat analysis"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3088-915X","authenticated-orcid":false,"given":"Adrienne","family":"Moln\u00e1r","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Rodriguez Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7211-6094","authenticated-orcid":false,"given":"Toshitaka","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4109-7053","authenticated-orcid":false,"given":"Chiara","family":"Croce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2324-844X","authenticated-orcid":false,"given":"Michael J.","family":"Kirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8601-0159","authenticated-orcid":false,"given":"Johan","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Stoop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wells A.","family":"Messersmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Schulick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3777-6887","authenticated-orcid":false,"given":"Oskar","family":"Franklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Del Chiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hpb.2026.04.451_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.hpb.2026.04.451_bib2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hpb.2026.04.451_bib3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2012.7352","article-title":"Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial","volume":"308","author":"Neoptolemos","year":"2012","journal-title":"JAMA"},{"issue":"10073","key":"10.1016\/j.hpb.2026.04.451_bib4","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"The Lancet"},{"issue":"25","key":"10.1016\/j.hpb.2026.04.451_bib5","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.hpb.2026.04.451_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.1031","article-title":"National Trends in the Use of Neoadjuvant Therapy Before Cancer Surgery in the US From 2004 to 2016","volume":"4","author":"Aquina","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.hpb.2026.04.451_bib7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.hpb.2019.06.019","article-title":"The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis","volume":"22","author":"Mackay","year":"2020","journal-title":"HPB"},{"issue":"14","key":"10.1016\/j.hpb.2026.04.451_bib8","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer: The CONKO-001 Randomized Trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.hpb.2026.04.451_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2023.7872","article-title":"Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands","author":"Mackay","year":"2024","journal-title":"JAMA Surg"},{"issue":"11","key":"10.1016\/j.hpb.2026.04.451_bib10","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1200\/JCO.22.01134","article-title":"Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial","volume":"41","author":"Tempero","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.hpb.2026.04.451_bib11","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","article-title":"Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma","volume":"267","author":"Groot","year":"2018","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.hpb.2026.04.451_bib12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.hpb.2021.09.004","article-title":"Preoperative predictors for early and very early disease recurrence in patients undergoing resection of pancreatic ductal adenocarcinoma","volume":"24","author":"Daamen","year":"2022","journal-title":"HPB"},{"issue":"3","key":"10.1016\/j.hpb.2026.04.451_bib13","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","article-title":"Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial","volume":"7","author":"Sohal","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.hpb.2026.04.451_bib14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.annonc.2022.09.161","article-title":"Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group","volume":"34","author":"Seufferlein","year":"2023","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"1","key":"10.1016\/j.hpb.2026.04.451_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100771","article-title":"Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Uson Junior","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.hpb.2026.04.451_bib16","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejca.2021.10.023","article-title":"Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials","volume":"160","author":"van Dam","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.hpb.2026.04.451_bib17","article-title":"Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial","volume":"21","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hpb.2026.04.451_bib18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","article-title":"Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial","volume":"9","author":"Labori","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.hpb.2026.04.451_bib19","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/MPA.0000000000001345","article-title":"Benefit of Gemcitabine\/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX","volume":"48","author":"Vreeland","year":"2019","journal-title":"Pancreas"},{"issue":"3","key":"10.1016\/j.hpb.2026.04.451_bib20","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1245\/s10434-021-10991-2","article-title":"Neoadjuvant Chemotherapy Switch in Borderline Resectable\/Locally Advanced Pancreatic Cancer","volume":"29","author":"Alva-Ruiz","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.hpb.2026.04.451_bib21","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"10.1016\/j.hpb.2026.04.451_bib23","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.hpb.2026.04.451_bib24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4292\/wjgpt.v11.i2.25","article-title":"Validation of American Joint Committee on Cancer 8th edition of TNM staging in resected distal pancreatic cancer","volume":"11","author":"Yin","year":"2020","journal-title":"World J Gastrointest Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.hpb.2026.04.451_bib25","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"7","key":"10.1016\/j.hpb.2026.04.451_bib26","first-page":"1135","article-title":"Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution","volume":"32A","author":"Buccheri","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"1","key":"10.1016\/j.hpb.2026.04.451_bib27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000521288","article-title":"Charlson Comorbidity Index: A Critical Review of Clinimetric Properties","volume":"91","author":"Charlson","year":"2022","journal-title":"Psychother Psychosom"},{"issue":"19","key":"10.1016\/j.hpb.2026.04.451_bib28","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hpb.2026.04.451_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1); Response assessment in solid tumours (RECIST): Version 1.1 and supporting papers45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.hpb.2026.04.451_bib30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of Surgical Complications","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.hpb.2026.04.451_bib31","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.surg.2016.11.014","article-title":"The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After","volume":"161","author":"Bassi","year":"2017","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.hpb.2026.04.451_bib32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.surg.2007.02.001","article-title":"Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition","volume":"142","author":"Wente","year":"2007","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.hpb.2026.04.451_bib33","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.surg.2007.05.005","article-title":"Delayed gastric emptying (DGE) after pancreatic surgery: A suggested definition by the International Study Group of Pancreatic Surgery (ISGPS)","volume":"142","author":"Wente","year":"2007","journal-title":"Surgery"},{"issue":"6","key":"10.1016\/j.hpb.2026.04.451_bib34","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.hpb.2020.01.001","article-title":"Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis","volume":"22","author":"Ye","year":"2020","journal-title":"HPB"},{"issue":"5","key":"10.1016\/j.hpb.2026.04.451_bib35","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S2468-1253(24)00054-2","article-title":"NORPACT-1: implications for future trials","volume":"9","author":"Snyder","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.hpb.2026.04.451_bib36","doi-asserted-by":"crossref","first-page":"8666","DOI":"10.1038\/s41598-018-26811-9","article-title":"The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis","volume":"8","author":"Tong","year":"2018","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.hpb.2026.04.451_bib37","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/s43018-023-00628-6","article-title":"Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC","volume":"4","author":"Zhou","year":"2023","journal-title":"Nat Cancer"},{"issue":"4","key":"10.1016\/j.hpb.2026.04.451_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249885","article-title":"Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection","volume":"16","author":"Sugawara","year":"2021","journal-title":"PLOS ONE"},{"issue":"11","key":"10.1016\/j.hpb.2026.04.451_bib39","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1001\/jamasurg.2019.3337","article-title":"Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial","volume":"154","author":"Jones","year":"2019","journal-title":"JAMA Surg"},{"issue":"8","key":"10.1016\/j.hpb.2026.04.451_bib40","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/bjs.11115","article-title":"Impact of resection margin status on recurrence and survival in pancreatic cancer surgery","volume":"106","author":"Tummers","year":"2019","journal-title":"Br J Surg"},{"issue":"16_suppl","key":"10.1016\/j.hpb.2026.04.451_bib41","doi-asserted-by":"crossref","first-page":"TPS4204","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS4204","article-title":"Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer","volume":"41","author":"Chawla","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hpb.2026.04.451_bib42","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1186\/s12885-023-11141-5","article-title":"Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial","volume":"23","author":"van Dam","year":"2023","journal-title":"BMC Cancer"}],"container-title":["HPB"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X26005964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X26005964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:58:23Z","timestamp":1786017503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1365182X26005964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1365182X26005964"],"URL":"https:\/\/doi.org\/10.1016\/j.hpb.2026.04.451","relation":{},"ISSN":["1365-182X"],"issn-type":[{"value":"1365-182X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant multiagent chemotherapy or upfront surgery for primary resectable pancreatic cancer \u2013 A retrospective intention-to-treat analysis","name":"articletitle","label":"Article Title"},{"value":"HPB","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hpb.2026.04.451","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}